# A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

> **NCT07376707** · PHASE1 · RECRUITING · sponsor: **Hefei TG ImmunoPharma Co., Ltd.** · enrollment: 194 (estimated)

## Conditions studied

- CRC (Colorectal Cancer)
- Melanoma (Skin Cancer)
- HCC - Hepatocellular Carcinoma
- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** TGI-5

## Key facts

- **NCT ID:** NCT07376707
- **Lead sponsor:** Hefei TG ImmunoPharma Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07376707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07376707, "A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07376707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*